Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)

V. Charlton-Menys · D. J. Betteridge · H. Colhoun ·
J. Fuller · M. France · G. A. Hitman · S. J. Livingstone ·
H. A. W. Neil · C. B. Newman · M. Szarek ·
D. A. DeMicco · P. N. Durrington

Published online: 17 December 2008
© Springer-Verlag 2008

Erratum to: *Diabetologia* DOI 10.1007/s00125-008-1176-8

The authors apologise for the following mistakes in this paper:

Abstract

The areas under the receiver operator curve for the ApoB:ApoA-I and the LDLC to HDLC ratios [corrected from 'LDLC to HDL-HDLC ratios'], although not significantly different from each other, were greater ($p=0.0005$ and $p=0.0125$ respectively) than that of non-HDLC:HDLC.

Discussion, paragraph 2

However, by ROC analysis, although clearly better [corrected from 'although not clearly better'] than non-HDLC:HDLC, the ApoB:ApoA-I ratio did not significantly improve on LDLC:HDLC.

Discussion, penultimate paragraph

In epidemiological studies, stroke incidence is also less strongly associated [corrected from 'also strongly associated'] with lipoproteins that are associated with CHD [31, 32].

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-008-1176-8>.

V. Charlton-Menys · P. N. Durrington (✉)
Cardiovascular Research Group,
School of Clinical & Laboratory Sciences,
Core Technology Facility (3rd Floor),
University of Manchester,
46 Grafton Street,
Manchester M13 9NT, UK
e-mail: pdurrington@manchester.ac.uk

D. J. Betteridge
Department of Medicine, Jules Thorne Institute,
The Middlesex Hospital,
London, UK

H. Colhoun
Department of Public Health, University of Dundee,
Dundee, UK

J. Fuller · S. J. Livingstone
Department of Epidemiology & Public Health,
University College London,
London, UK

M. France
Department of Clinical Biochemistry,
Manchester Royal Infirmary,
Manchester, UK

G. A. Hitman
Centre for Diabetes and Metabolic Medicine,
Queen Mary's School of Medicine University of London,
London, UK

H. A. W. Neil
Division of Public Health & Primary Health Care,
University of Oxford,
Oxford, UK

C. B. Newman
Department of Medicine,
New York University School of Medicine,
New York, USA

M. Szarek · D. A. DeMicco
Pfizer Global Medical,
New York, USA